The Newest FDA-Approved Obesity Drug Is Also the Oldest
Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.
3 Stocks Poised for Eye-Popping Gains in 2015
Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.
3 Biotech Stocks I Don't Want for Christmas
I’d prefer coal in my stocking to these three troubled biotech stocks.
Buying These 3 Stocks Is Like Making a Bet in a Burning House
Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?
New Obesity Drug Available Soon
Orexigen is close to getting Mysimba on the market in Europe.